Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
about
Clinical relevance of circulating cell-free microRNAs in ovarian cancerMolecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentAntiangiogenic therapies in ovarian cancerPhase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905).Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis.Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report.Ovarian cancer stem cells: still an elusive entity?Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Prediction of therapy response in ovarian cancer: Where are we now?Role of A-Kinase anchor protein (AKAP4) in growth and survival of ovarian cancer cellsHighlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology.Negative trials in ovarian cancer: is there such a thing as too much optimism?Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.BRCA mutations in the manifestation and treatment of ovarian cancer.Optimizing treatment in recurrent epithelial ovarian cancer.Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients.Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice.Advances in ovarian cancer therapy.The role of Cediranib in ovarian cancer.Therapeutic Impact of Nanoparticle Therapy Targeting Tumor-Associated Macrophages.The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis.The rise of genomic profiling in ovarian cancer.Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.Nintedanib in ovarian cancer.The role of tumor microenvironment in resistance to anti-angiogenic therapy.The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials
P2860
Q26747154-EB387EAA-AE1A-4595-B873-DE5F2F29B5CBQ28066904-1E855F52-EA8C-4524-8258-AC2AF021B84AQ28073722-11430B70-4FA6-44DB-8EE5-ECDCBE917AFBQ33442594-E711DF9D-7007-4680-B732-85089FCA35A1Q33563963-A0E1C704-E9AF-496E-8CFA-32033297918AQ37661852-E79979C6-0F6A-4459-837E-AE47B6CFD32AQ37712356-CBD698C9-8A52-4D3B-B76B-A292FCC6E597Q37713683-8B65E77D-594C-4E3F-BBF8-102E10BE6A1DQ38822258-DE1A9880-CCA5-439C-A8EB-BDD73B06CF60Q38879397-49B5BC5F-23D3-4FBF-A8E6-9CD67F4A61F7Q39036230-2BC2E9C8-E2DC-44A8-8B03-77BA6869E398Q39210287-53F2D8AE-94C0-4F2E-AE56-6EEA0A0BD48FQ39263260-A3E2DC93-B1FC-4167-9E0A-71305E573D4BQ41593068-0844CD3E-82A0-44EA-9EAE-8DCAB490820FQ42341404-F0CC638B-6847-480C-942A-F93FF5D70494Q42347314-747F6B13-B394-419D-BC20-4080A1D309F3Q42694284-84A61858-4F9B-4AB6-A11F-A7849D7AC48CQ46270437-0F67CB48-E961-480B-BDBF-8C501C56216DQ47096976-95C0111E-53C8-4E36-887A-DEF4E2677AF1Q47134293-8C3A2A09-2EC0-40E6-A811-51C79E84AE5DQ47549019-5B72DE14-9B8C-4A1C-A131-3B4542046FA5Q47685928-B4DAA2FF-A427-4079-B577-67FBA94C86E9Q47903356-524FE633-638E-4A0B-89ED-B825F424B33DQ48104995-9484DFAC-45C2-420D-B17F-D79E417A7858Q49966031-06C37CE1-905C-47A0-839E-87E533DB1BE1Q50042447-364D2C7B-EE98-4CEC-8667-75D358FC27F7Q50129142-A407B060-2A10-4467-820D-F8A75C798EFCQ50345037-D0CFC053-5F9E-43B5-BD5E-F6AEFDC49B28Q50885562-B940C7EA-9E6C-4221-89B7-BCD9E39D8EFEQ51824301-1AC6097B-B9D2-48A2-8444-50D3C879712AQ52645823-007ADC69-D5AD-48AD-BA92-BF7A34C433F5Q55181578-BBCA04BC-771A-4EDF-9D7F-437AFC91EDB7Q55217694-0ECECBCE-A247-48E5-9809-6845390A8253Q55416207-582F7C28-F103-40C0-B190-EA645F53EB6EQ58706801-0EEC577E-526F-461F-92C2-C268054C9DCB
P2860
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Cediranib in patients with rel ...... cebo-controlled phase 3 trial.
@ast
Cediranib in patients with rel ...... cebo-controlled phase 3 trial.
@en
Cediranib in patients with rel ...... cebo-controlled phase 3 trial.
@nl
type
label
Cediranib in patients with rel ...... cebo-controlled phase 3 trial.
@ast
Cediranib in patients with rel ...... cebo-controlled phase 3 trial.
@en
Cediranib in patients with rel ...... cebo-controlled phase 3 trial.
@nl
prefLabel
Cediranib in patients with rel ...... cebo-controlled phase 3 trial.
@ast
Cediranib in patients with rel ...... cebo-controlled phase 3 trial.
@en
Cediranib in patients with rel ...... cebo-controlled phase 3 trial.
@nl
P2093
P50
P921
P1154
2-s2.0-84964322497
P1433
P1476
Cediranib in patients with rel ...... acebo-controlled phase 3 trial
@en
P2093
Adrian Cook
Ann Marie Swart
Antonio González-Martín
Daniel Stark
Elizabeth Clark
Elizabeth Eisenhauer
Fharat Raja
Gordon J S Rustin
ICON6 collaborators
P304
P356
10.1016/S0140-6736(15)01167-8
P407
P577
2016-03-01T00:00:00Z